De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Cardiol Therapeutics Beheer
Beheer criteriumcontroles 1/4
De CEO Cardiol Therapeutics' is David Elsley, benoemd in Jan2017, heeft een ambtstermijn van 7.75 jaar. De totale jaarlijkse vergoeding van { bedraagt CA$ 748.10K, bestaande uit 70.2% salaris en 29.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.72% van de aandelen van het bedrijf, ter waarde CA$ 3.24M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 2.8 jaar.
Belangrijke informatie
David Elsley
Algemeen directeur
CA$748.1k
Totale compensatie
| Percentage CEO-salaris | 70.2% |
| Dienstverband CEO | 7.8yrs |
| Eigendom CEO | 1.7% |
| Management gemiddelde ambtstermijn | 3.8yrs |
| Gemiddelde ambtstermijn bestuur | 2.8yrs |
Recente managementupdates
Recent updates
We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate
Sep 12
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?
May 01Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?
Jan 06Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?
Sep 13We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully
May 24We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth
Jan 20We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth
Aug 10We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn
Apr 17Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
Dec 09We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully
Aug 19Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
Apr 18Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth
Jan 03Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CA$29m |
| Mar 31 2024 | n/a | n/a | -CA$30m |
| Dec 31 2023 | CA$748k | CA$525k | -CA$28m |
| Sep 30 2023 | n/a | n/a | -CA$28m |
| Jun 30 2023 | n/a | n/a | -CA$30m |
| Mar 31 2023 | n/a | n/a | -CA$29m |
| Dec 31 2022 | CA$654k | CA$525k | -CA$31m |
| Sep 30 2022 | n/a | n/a | -CA$30m |
| Jun 30 2022 | n/a | n/a | -CA$32m |
| Mar 31 2022 | n/a | n/a | -CA$32m |
| Dec 31 2021 | CA$1m | CA$455k | -CA$32m |
| Sep 30 2021 | n/a | n/a | -CA$35m |
| Jun 30 2021 | n/a | n/a | -CA$30m |
| Mar 31 2021 | n/a | n/a | -CA$27m |
| Dec 31 2020 | CA$517k | CA$450k | -CA$21m |
| Sep 30 2020 | n/a | n/a | -CA$14m |
| Jun 30 2020 | n/a | n/a | -CA$13m |
| Mar 31 2020 | n/a | n/a | -CA$13m |
| Dec 31 2019 | CA$450k | CA$450k | -CA$14m |
| Sep 30 2019 | n/a | n/a | -CA$20m |
| Jun 30 2019 | n/a | n/a | -CA$21m |
| Mar 31 2019 | n/a | n/a | -CA$19m |
| Dec 31 2018 | CA$713k | CA$363k | -CA$16m |
Compensatie versus markt: De totale vergoeding ($USD 554.49K ) David } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 177.89K ).
Compensatie versus inkomsten: De vergoeding van David is gestegen terwijl het bedrijf verliesgevend is.
CEO
David Elsley
7.8yrs
Tenure
CA$748,100
Compensatie
Mr. David G. Elsley, MBA, has been the President, Chief Executive Officer and Director of Cardiol Therapeutics Inc since January 19, 2017. Mr. Elsley is a business leader with a proven track record of deve...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 7.8yrs | CA$748.10k | 1.72% CA$ 3.1m | |
| CFO, Corporate Secretary & Director | 6.2yrs | CA$294.80k | 0.16% CA$ 283.8k | |
| Chief Operating Officer | 3.8yrs | CA$515.90k | 0.043% CA$ 77.4k | |
| Chief Medical Officer & Head of Research & Development | 3.6yrs | CA$746.56k | 0.45% CA$ 811.1k | |
| Investor Relations | no data | geen gegevens | geen gegevens | |
| Vice President of Corporate Development | less than a year | geen gegevens | geen gegevens |
3.8yrs
Gemiddelde duur
Ervaren management: Het managementteam van CRDL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 7.8yrs | CA$748.10k | 1.72% CA$ 3.1m | |
| CFO, Corporate Secretary & Director | 2.4yrs | CA$294.80k | 0.16% CA$ 283.8k | |
| Independent Director | 4.8yrs | CA$60.00k | 0.20% CA$ 367.7k | |
| Independent Director | 2.6yrs | CA$76.92k | 0.14% CA$ 258.0k | |
| Independent Director | 6.8yrs | CA$58.00k | 0.67% CA$ 1.2m | |
| Independent Director | 3.1yrs | CA$71.52k | 1.22% CA$ 2.2m | |
| Member of Scientific Advisory Board | 2.8yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 2.8yrs | geen gegevens | geen gegevens | |
| Independent Director | 2.4yrs | CA$82.32k | 0.17% CA$ 309.6k | |
| Independent Chairman | 6.2yrs | CA$112.68k | 0.32% CA$ 568.9k | |
| Member of Scientific Advisory Board | 2.8yrs | geen gegevens | geen gegevens |
2.8yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van CRDL wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.8 jaar), wat duidt op een nieuw bestuur.